Cell-based drug screens for regulators of gene expression
View Patent ↗The invention provides methods and compositions for screening for pharmacological agents which regulate gene expression in mammals. An exemplary assay involves (a) contacting a mammalian cell comprising a knock-in mutant of a targeted native allele encoding a reporter of gene expression, wherein the expression of the reporter is under the control of the gene expression regulatory sequences of the native allele, with a candidate agent under conditions whereby but for the presence of the agent, the reporter is expressed at a first expression level; and, (b) measuring the expression of the reporter to obtain a second expression level, wherein a difference between the first and second expression levels indicates that the candidate agent modulates gene expression.
1. An isolated genetic knock-in cell, wherein said cell is, or is a progeny of, a genetic knock-in primary cell obtained from a transgenic mouse made by homologous recombination of a targeted native allele with a transgene comprising a sequence encoding a reporter flanked by flanking sequences which effect the homologous recombination of said transgene with said native allele, wherein the expression of said reporter is under the control of native gene expression regulatory sequences of said native allele, and said native allele is selected from the group consisting of a mouse ob (leptin) allele, a mouse UCP-2 allele, a mouse Ob receptor allele, and a mouse STAT6 allele.
2. The genetic knock-in cell of claim 1 , wherein said knock-in cell results from the replacement of a portion of said native allele with a sequence encoding said reporter.
3. The genetic knock-in cell of claim 1 , wherein said reporter is luciferase.
4. A cell-based method for screening for modulators of a targeted gene expression, said method comprising steps:
(a) isolating a genetic knock-in primary cell from a transgenic mouse made by homologous recombination of a targeted native allele with a transgene comprising a sequence encoding a reporter flanked by flanking sequences which effect the homologous recombination of said transgene with said native allele, wherein the expression of said reporter is under the control of native gene expression regulatory sequences of said native allele, and said native allele is selected from the group consisting of a mouse ob (leptin) allele, a mouse UCP-2 allele, a mouse Ob receptor allele, and a mouse STAT6 allele;
(b) determining a first reporter expression level in a first isolated cell wherein said first isolated cell is, or is a progeny of said genetic knock-in cell;
(c) contacting a second isolated cell wherein said second isolated cell is, or is a progeny of said genetic knock-in cell with a candidate agent under conditions whereby but for the presence of said agent, said reporter is expressed at said first reporter expression level;
(d) determining a second reporter expression level in said second isolated cell;
(e) comparing said first expression level with said second expression level, wherein a difference between said first and second expression levels indicates that said candidate agent modulates the targeted gene expression.
5. The method of claim 4 , wherein said second isolated cell is in a suspension of identical cells, said reporter is luciferase, said contacting step comprises depositing aliquots of said suspension into wells of a plate under sterile conditions, adding said agent to said aliquots and incubating said aliquots 6–18 hours, and said measuring step comprises adding a lysing detergent, ATP, coenzyme A and luciferin to said aliquots and measuring luciferase-derived luminescence.
6. The genetic knock-in cell of claim 1 , wherein said knock-in cell is a blood borne cell.
7. The genetic knock-in cell of claim 1 , wherein said knock-in cell is a lymphocyte or macrophage.
8. The genetic knock-in primary cell of claim 1 , wherein said knock-in cell is a structurally associated cell.
9. The genetic knock-in primary cell of claim 1 , wherein said knock-in cell is a hepatocyte, muscle cell or neuron.
10. The method of claim 4 , wherein said genetic knock-in cell is a blood borne cell.
11. The method of claim 4 , wherein said genetic knock-in cell is a lymphocyte or macrophage.
12. The method of claim 4 , wherein said genetic knock-in cell is a structurally associated cell.
13. The method of claim 4 , wherein said genetic knock-in cell is a hepatocyte, muscle cell or neuron.
14. The genetic knock-in cell of claim 1 , wherein said native allele is a mouse ob (leptin) allele.
15. The genetic knock-in cell of claim 1 , wherein said native allele is a mouse UCP-2 allele.
16. The genetic knock-in cell of claim 1 , wherein said native allele is a mouse Ob receptor allele.
17. The genetic knock-in cell of claim 1 , wherein said native allele is a mouse STAT6 allele.
18. The method of claim 4 , wherein said native allele is a mouse ob (leptin) allele.
19. The method or claim 4 , wherein said native allele is a mouse UCP-2 allele.
20. The method of claim 4 , wherein said native allele is a mouse Ob receptor allele.
21. The method of claim 4 , wherein said native allele is a mouse STAT6 allele.